Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Wheelchair

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    78 result(s) found for: Wheelchair. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-000069-19 Sponsor Protocol Number: MS700568_0026 Start Date*: 2019-07-12
    Sponsor Name:Merck KGaA
    Full Title: Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously ...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) PT (Completed) EE (Completed) BG (Completed) AT (Completed) LT (Completed) BE (Completed) PL (Completed) ES (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-000735-26 Sponsor Protocol Number: AGN/HO/SPA/001-191622 Start Date*: 2007-06-18
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicentre, Double-Blind, Prospective, Randomised, European and Canadian Study to Evaluate Patient Outcomes and Costs of Managing Adults with Spasticity and Associated Focal Spasticity.
    Medical condition: Spasticity and Associated Focal Spasticity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004040-29 Sponsor Protocol Number: CY5031 Start Date*: Information not available in EudraCT
    Sponsor Name:Cytokinetics Inc
    Full Title: A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS).
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000389-16 Sponsor Protocol Number: 1821-FSH-301 Start Date*: 2022-08-08
    Sponsor Name:Fulcrum Therapeutics
    Full Title: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy
    Medical condition: Facioscapulohumeral Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10064087 Facioscapulohumeral muscular dystrophy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004520-10 Sponsor Protocol Number: ACNS1021 Start Date*: 2019-06-25
    Sponsor Name:National Cancer Institute (NCI)
    Full Title: 2018-004520-10
    Medical condition: Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003319-64 Sponsor Protocol Number: S3B40042 Start Date*: 2007-07-05
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomised, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-006118-17 Sponsor Protocol Number: B3I105940 Start Date*: 2006-08-17
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004946-27 Sponsor Protocol Number: E2020-A001-219 Start Date*: 2017-05-18
    Sponsor Name:Eisai Inc.
    Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With D...
    Medical condition: Down Syndrome, Cognitive Dysfunction
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-013295-48 Sponsor Protocol Number: 22505 Start Date*: 2009-09-04
    Sponsor Name:Århus University Hospital, Department of Dermatology
    Full Title: Treatment of patients with Nephrogenic Systemic Fibrosis(NSF) with Imatinib Mesylate(Glivec). An open label clinical trial among patients with moderate to severe NSF.
    Medical condition: Nephrogenic Systemic Fibrosis (NSF) is a fibrosing disease strongly associated with Gadolinium Based Contrast Agents(GBCA). Hard dermal plaques appear on legs, arms and abdomen. The lesions involve...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067467 Nephrogenic systemic fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-005103-27 Sponsor Protocol Number: BETASBMA Start Date*: 2021-11-18
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: A PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CLENBUTEROL IN PATIENTS WITH SPINAL AND BULBAR MUSCULAR ATROPHY (SBMA)
    Medical condition: Motor neuron disease characterized by atrophy and muscle weakness in the spinal and bulbar region
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10068597 Bulbospinal muscular atrophy congenital PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004427-37 Sponsor Protocol Number: ESPP001 Start Date*: 2014-10-01
    Sponsor Name:PARENT PROJECT ONLUS
    Full Title: Multicentre, randomised, double-blind, dose titration design in patients with Duchenne muscular dystrophy to evaluate the efficacy and the tolerability of the combinations of Ibuprofen (200 mg bid)...
    Medical condition: Restrictive respiratory syndrome with frequent pulmonary infections and cardiomyopathy. wasting of skeletal muscle, severe local inflammation and, at least initially, muscle regeneration.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10064571 Gene mutation PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006485-42 Sponsor Protocol Number: 35GA0608 Start Date*: 2007-03-08
    Sponsor Name:Q-Med AB
    Full Title: Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects with Osteoarthritis of the Knee
    Medical condition: Osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000705-23 Sponsor Protocol Number: CBYM338B2203 Start Date*: 2014-02-09
    Sponsor Name:Novartis Farma SpA
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52...
    Medical condition: Sporadic Inclusion Body Myositis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10066407 Inclusion body myositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Completed) DE (Completed) BE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001176-31 Sponsor Protocol Number: 19215 Start Date*: 2017-09-22
    Sponsor Name:Bayer AG,
    Full Title: BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies
    Medical condition: Clinically-isolated syndrome (CIS) and multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) SE (Completed) GB (Completed) AT (Completed) CZ (Completed) FI (Completed) DK (Completed) BE (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001953-10 Sponsor Protocol Number: ALD-102 Start Date*: 2013-12-13
    Sponsor Name:bluebird bio, Inc.
    Full Title: A phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti D lentiviral vector for the treatment of cerebral adrenoleukodystrophy (CALD)
    Medical condition: Cerebral Adrenoleukodystrophy (CALD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051260 Adrenoleukodystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003696-19 Sponsor Protocol Number: E7080-G000-230 Start Date*: 2020-02-28
    Sponsor Name:Eisai Ltd
    Full Title: A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adoles...
    Medical condition: Relapsed or Refractory Osteosarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) FR (Completed) BE (Completed) IE (Completed) NL (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-004503-39 Sponsor Protocol Number: IG1104 Start Date*: 2015-01-28
    Sponsor Name:Instituto Grifols, S.A.
    Full Title: A multicenter, prospective, randomized, placebo-controlled, double-blind, parallel-group clinical trial to assess the efficacy and safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF...
    Medical condition: Patients with Post-polio syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10036239 Post polio syndrome PT
    17.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) ES (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024566-22 Sponsor Protocol Number: DMD114118 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research and Development LTD
    Full Title: A double-blind, escalating dose, randomized, placebo-controlled study to assess the pharmacokinetics, safety and tolerability of single subcutaneous injections of GSK2402968 in non-ambulant subject...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10013801 Duchenne muscular dystrophy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: FR (Ongoing) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002635-41 Sponsor Protocol Number: 15HI53 Start Date*: 2018-09-26
    Sponsor Name:Great Ormond Street Hospital
    Full Title: A paediatric phase I/II study of intermittent dosing of the MEK-1 inhibitor selumetinib in children with neurofibromatosis type-1 and inoperable plexiform neurofibroma and/or progressive optic path...
    Medical condition: Neurofibromatosis type 1 associated plexiform neurofibromas Neurofibromatosis type 1 associated progressive or relapsed optic pathway glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    20.0 100000004864 10065866 Plexiform neurofibroma LLT
    20.0 100000004864 10030935 Optic nerve glioma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-005432-33 Sponsor Protocol Number: UX001-CL301 Start Date*: 2016-06-07
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion...
    Medical condition: GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), Distal Myopathy with Rimmed Vacuoles (DMRV), Nonaka’s disease, or quadriceps sparing myopathy (QSM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10075048 Hereditary inclusion body myopathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 17:43:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA